HOme USability Evaluation

To validate the usability and safety of the Liberty Analyser.

Why the study stopped: Change in trial pipeline. Study no longer required.

Withdrawn

Looking for future studies?

Notify Me

Key information

Conditions

Cancer Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Undergoing systemic anti-cancer therapy (SACT)
Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, 2 at enrolment
Adequate English language skills (not requiring a translator) to participate in participant training and use the Entia Liberty analyser
Patients capable of providing written informed consent

Exclusion criteria

History or current diagnosis of haematological malignancy
Patients with eyesight or hearing limitations or other disabilities that preclude the use of the Entia Liberty analyser or participation in training
Inadequate use and understanding of the English language, requiring a translator

Treatment and study plan

Entia Liberty

Device

Home monitoring

Primary outcomes

The Entia Liberty Analyser is easy to use

Time frame: Through study completion, 1 day

Users can easily carry out a test using the Entia Liberty Analyser
The Entia Liberty Analyser is safe to use

Time frame: Through study completion, 1 day

Results obtained using the Entia Liberty Analyser are valid and reliable

Sponsors and collaborators

Lead sponsor

Entia Ltd

Industry

Registry information

Acronym: HOUSE

Important dates

Study start: 2024
Primary completion: 2024
Study completion: 2024
First posted: Nov 18, 2023
Registry last updated: Sep 11, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Withdrawn